SCHEMBL20122874

SCHEMBL20122874

Cc1nccc2c1[nH]c1c(-c3ccc(OCC4CCN(C)C4)cc3)cc(Cl)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 6/20 0.46
MAOB P27338 2/20 0.46
ROCK1 Q13464 2/20 0.38
DYRK1A Q13627 2/20 0.38
HTR2C P28335 2/20 0.38
KDM4E B2RXH2 1/20 0.38
DYRK3 O43781 1/20 0.38
CCNT1 O60563 1/20 0.38
CCNB2 O95067 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
CDK1 P06493 1/20 0.38
CYP3A4 P08684 1/20 0.38
ADRA2A P08913 1/20 0.38
CYP2D6 P10635 1/20 0.38
CCNB1 P14635 1/20 0.38
HPGD P15428 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
CCNA2 P20248 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29756315 1.00 MAOA (0.46) MAOAMAOBROCK1DYRK1AHTR2C
SCHEMBL20122829 0.90 MAOA (0.54) MAOAMAOBROCK1DYRK1AHTR2C
SCHEMBL30909497 0.90 MAOA (0.54) MAOAMAOBROCK1DYRK1AHTR2C
SCHEMBL20122951 0.80 MAOA (0.47) MAOAMAOBROCK1DYRK1AHTR2C
SCHEMBL30664264 0.80 MAOA (0.47) MAOAMAOBROCK1DYRK1AHTR2C
SCHEMBL29756312 0.80 MAOA (0.54) MAOAROCK1DYRK1AHTR2CKDM4E
SCHEMBL20122797 0.80 MAOA (0.54) MAOAROCK1DYRK1AHTR2CKDM4E
SCHEMBL20123019 0.80 MAOA (0.45) MAOAMAOBROCK1DYRK1AHTR2C
SCHEMBL30664187 0.80 MAOA (0.45) MAOAMAOBROCK1DYRK1AHTR2C
SCHEMBL20122867 0.78 MAOA (0.47) MAOAMAOBROCK1DYRK1AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110382496-B Substituted pyrido [3,4-b ] indoles for the treatment of cartilage disorders 赛诺菲 2022-08-09 CN claimed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP claimed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
CN-110382496-B Substituted pyrido [3,4-b ] indoles for the treatment of cartilage disorders 赛诺菲 2022-08-09 CN disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
EP-3535263-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS Sanofi (FR) 2019-09-11 EP disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 MAOA 245/4885MAOB 49/4885ROCK1 531/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 MAOA 245/4885MAOB 49/4885ROCK1 531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.